ES2102347T3 - Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv. - Google Patents

Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.

Info

Publication number
ES2102347T3
ES2102347T3 ES88301425T ES88301425T ES2102347T3 ES 2102347 T3 ES2102347 T3 ES 2102347T3 ES 88301425 T ES88301425 T ES 88301425T ES 88301425 T ES88301425 T ES 88301425T ES 2102347 T3 ES2102347 T3 ES 2102347T3
Authority
ES
Spain
Prior art keywords
hiv
domain
remains
useful
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88301425T
Other languages
English (en)
Inventor
Phillip W Berman
Timothy J Gregory
Lawrence A Lasky
Gerald R Nakamura
Eric J Patzer
John S Patton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ES2102347T3 publication Critical patent/ES2102347T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PROTEINA DE FUNDA DE VIRUS DE INMUNODEFICIENCIA HUMANO, O SUS FRAGMENTOS, QUE SON CAPACES DE ENLAZAR AL RECEPTOR DE LINFOCITO DE REFUERZO T4, SON UTILES EN DOSIS TERAPEUTICAMENTE EFICACES PARA EL TRATAMIENTO DE DESORDENES O ENFERMEDADES INMUNOINFLAMATORIAS. LOS RESTOS DE AMINOACIDOS, QUE CONSTITUYEN PARTE ESENCIAL DEL DOMINIO DE UNION DEL RECEPTOR T4 DE FUNDA DE HIV CAEN DENTRO DE UNA SECUENCIA DE 64 RESTOS, QUE SE EXTIENDE DESDE 411 A 454 RESTOS DEL AISLADO 3B. ESTE DOMINIO ES UTIL COMO COMPONENTE DE VACUNA, O COMO BLANCO DE CELULAS T CITOTOXICAS CUANDO SE CONJUGA CON UNA SUSTANCIA ENLAZANTE DE CELULA BLANCO. LA FUNDA DE HIV, QUE ESTA LIBRE DE UN DOMINIO ENLAZANTE DE RECEPTOR T4 FUNCIONAL, ES UTIL COMO VACUNA PARA INMUNIZAR CONTRA LA INFECCION POR HIV. TAMBIEN SE PROPORCIONAN ANTICUERPOS CAPACES DE ENLAZAR ESTE DOMINIO PARA USO TERAPEUTICO Y DE DIAGNOSTICO. SE DESCRIBE UNA INMUNOTOXINA, QUE COMPRENDE UN ANTICUERPO MONOCLONAL PARA UN ANTIGENO DE SUPERFICIE CELULAR CODIFICADA VIRALMENTE. TAMBIEN SE DESCRIBE UN METODO PARA ELIMINAR CELULAS AFECTADAS VIRALMENTE, TALES COMO CELULAS HIV INFECTADAS, QUE CONSISTE EN ADMINISTRAR A LAS CELULAS INFECTADAS UNA CANTIDAD TERAPEUTICAMENTE EFICAZ DE LA INMUNOTOXINA.
ES88301425T 1987-02-20 1988-02-19 Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv. Expired - Lifetime ES2102347T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1680987A 1987-02-20 1987-02-20
US5706187A 1987-06-01 1987-06-01
US15533688A 1988-02-12 1988-02-12

Publications (1)

Publication Number Publication Date
ES2102347T3 true ES2102347T3 (es) 1997-08-01

Family

ID=27360648

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88301425T Expired - Lifetime ES2102347T3 (es) 1987-02-20 1988-02-19 Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.

Country Status (6)

Country Link
EP (1) EP0279688B1 (es)
AT (1) ATE151638T1 (es)
CA (1) CA1330038C (es)
DE (1) DE3855869T2 (es)
ES (1) ES2102347T3 (es)
GR (1) GR3024051T3 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5017688A (en) * 1986-06-12 1991-05-21 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US4943627A (en) * 1986-06-12 1990-07-24 Biogen, Inc. Peptides involved in the pathogenesis of HIV infection
US5939074A (en) * 1986-12-30 1999-08-17 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptide antigens
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
CA1341285C (en) * 1988-02-12 2001-08-14 Chang Yi Wang Synthetic peptides for the detection of antibodies to hiv gp120 envelope protein for diagnosis of aids and pre-aids conditions and as vaccines
CA2003300A1 (en) * 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
US5731189A (en) * 1989-02-28 1998-03-24 New York University Human monoclonal antibodies to human immunodeficiency virus
DE69029937T2 (de) * 1989-04-25 1997-05-28 Tanox Biosystems Inc FÜr DIE CO4-BINDENDE DOMÄNE VON HIV SPEZIFISCHE ANTIKÖRPER
GB8912496D0 (en) * 1989-05-31 1989-07-19 Medical Res Council Vaccines
AU6523590A (en) * 1989-09-22 1991-04-18 Idec Pharmaceuticals Corporation Novel peptides associated with the cd4 binding region of gp120 and their methods of use
WO1991012021A2 (en) * 1990-02-13 1991-08-22 Oxford Virology Plc Therapeutic agents, and intermediates for the synthesis thereof
CA2078545A1 (en) * 1990-04-03 1991-10-04 Timothy J. Gregory Hiv envelope polypeptides
EP0651818B1 (en) * 1990-05-16 1999-01-07 Dana Farber Cancer Institute Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding
AU9072991A (en) * 1990-10-26 1992-05-26 Public Health Research Institute Of The City Of New York, Inc., The Neutralizing human monoclonal antibodies specific for the v3 loop and cd-4 binding site of hiv-1 gp120
US6228608B1 (en) * 1991-02-28 2001-05-08 Aquila Biopharmaceuticals, Inc. Recombinant FIV glycoprotein 160 and P24 gag protein
CA2114849C (en) * 1991-08-29 2007-04-24 Jay A. Berzofsky Multideterminant peptide antigens that stimulate helper t lymphocyte response to hiv in a range of human subjects
US5556744A (en) * 1992-05-29 1996-09-17 The Trustees Of The University Of Pennsylvania Methods and compositions for diagnosing and treating certain HIV infected patients
EP0708659A4 (en) 1993-06-07 2000-08-23 Genentech Inc HIV ENVELOPE POLYPEPTIDES
WO1995011010A1 (en) * 1993-10-22 1995-04-27 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
DE69415684T2 (de) * 1993-10-22 1999-06-10 Genentech Inc., San Francisco, Calif. Verfahren zur herstellung von mikrospharen mit einer wirbelschichtstufe
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
ZA975889B (en) * 1996-07-08 1998-02-23 Genentech Inc HIV envelope polypeptides and vaccine.
US6585979B1 (en) 1996-07-08 2003-07-01 Genentech, Inc. HIV envelope polypeptides and immunogenic composition

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4714613A (en) 1982-09-30 1987-12-22 The Albert Einstein College Of Medicine Of Yeshiva University Method of suppressing cell growth by immunotherapy
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
KR930000189B1 (ko) * 1984-10-18 1993-01-11 앵스뛰띠 빠스뙤르 임파선증과 후천성 면역 결핍증 바이러스의 항원을 제조하는 방법 및 이 항원에 대한 항체의 생산 방법
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
ATE138100T1 (de) 1984-12-24 1996-06-15 Genentech Inc Fusionen von aids-verwandten polypeptiden
DE3672624D1 (de) 1985-02-05 1990-08-23 Us Commerce Verfahren zum nachweis von htlv-iii neutralisierenden antikoerpern in sera.
AU592258B2 (en) * 1986-12-30 1990-01-04 United States of America, as represented by the Secretary, U.S. Department of Commerce, The Synthetic peptides which induce cellular immunity to the aids virus and aids viral proteins

Also Published As

Publication number Publication date
EP0279688A3 (en) 1989-09-13
CA1330038C (en) 1994-06-07
DE3855869T2 (de) 1997-10-02
GR3024051T3 (en) 1997-10-31
ATE151638T1 (de) 1997-05-15
DE3855869D1 (de) 1997-05-22
EP0279688A2 (en) 1988-08-24
EP0279688B1 (en) 1997-04-16

Similar Documents

Publication Publication Date Title
ES2102347T3 (es) Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
Weinhold et al. Cellular anti-GP120 cytolytic reactivities in HIV-1 seropositive individuals
Baldwin et al. Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes
ES2194836T3 (es) Peptidos para su uso en vacunacion e induccion de anticuerpos neutralizantes contra el virus de la inmunodeficiencia humana.
SE8604007L (sv) Vaccin och immunoanalyser for forvervat immunbristsyndrom (aids)
DE68927348D1 (de) Künstlicher impfstoff gegen aids-virus
ES2126620T3 (es) Retrovirus del grupo de los vih y su utilizacion.
JPH07506810A (ja) 自己抗原である病原性のｔ細胞エピトープおよびｂ細胞エピトープに対する寛容性を誘導するための合成ペプチドの使用
GB2255093A (en) Hiv-1 core protein fragments
JPS6485928A (en) Monoclonal antibody and peptide useful for therapy and diagnosis for hiv infection
BR9106303A (pt) Imonogeno humano composicao,celula de mamifero,peptido,vacina contra sintomas de esclerose multipla,metodo para tratar ou prevenir doenca com sintomas de esclerose multipla e conjunto para diagnosticar esclerose multipla
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
DE60221805T2 (de) Peptide mit affinität zu gp120, und ihre verwendungen
US5658569A (en) Anti-HIV-1 neutralizing antibodies
US5338829A (en) Peptides derived from human immunodeficiency virus-1 GP160
CA2073060A1 (en) Monoclonal antibody specific for non-immunodominant epitope of hiv proteins
Benjouad et al. Effect of sialic acid removal on the antibody response to the third variable domain of human immunodeficiency virus type‐1 envelope glycoprotein
Chen et al. HIV-1 gp41 binding proteins and antibodies to gp41 could inhibit enhancement of human Raji cell MHC class I and II expression by gp41
NO914725L (no) Cystein-tiolbeskyttede peptider for bruk ved immunologiske maalinger
JPS63294795A (ja) ヒト免疫不全ウイルス（ｈｉｖ）の検出と治療のための方法および物質
Chen et al. A common immunological epitope existing between HIV-1 gp41 and human interferon-α and-β
DE69433057D1 (de) Peptide zur verwendung bei der impfung und induktion neutralisierender antikörper gegen das menschliche immunschwäche-virus
Yu et al. Induction of High Levels of Epitope‐Specific Antibodies by Epitope/Peptide Candidate Vaccines against Human Immunodeficiency Virus Type‐1 (HIV‐1)
DK0426314T3 (da) HIV-relaterede peptider
DE68925202T2 (de) HIV-2-EHO-Retrovirus-Proteine und -Glycoproteine, Antikörper gegen sie, Verwendung für diagnostische Zwecke

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 279688

Country of ref document: ES